What is KPTI's current stock price?

As of now, KPTI is trading at $5.57, with a daily change of +1.18%.

What are the risks associated with KPTI stock?

KPTI Key risk is its Moderate, .

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

KPTI Stock Analysis & IQ Rating | Karyopharm Therapeutics

KPTI

Karyopharm Therapeutics

$5.57

+$0.07 | +1.18%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$ 13.35

MKT CAP

$ 93.78M

52W Low

$ 3.51

VOL

$ 923.00

P/E Ratio

N/A

AVG VOL

$ 245.78K

RSI

44.16

TREND

Downtrend

KPTI Stock IQ

Login to see Karyopharm Therapeutics (KPTI) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

KPTI Target Price

Login to display

Strengths

KPTI Rewards

Earnings are forecast to grow

KPTI Rewards

Outperform the market

Chart

$5.99 (-7.01%)

$6.02 (-7.48%)

$4.49 (+24.05%)

$0.85 (+555.29%)

1year

6month

3month

1month

KPTI Risk Level

KPTI has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Low volume

High volatilty

Moderate

LOW

HIGH

KPTI Analysts Opinion

KPTI overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

KPTI Analysts Opinion

KPTI Analysts opinion is positive and also has improved from the past 3 months

KPTI Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

62%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

100%

KPTI Street Sentiment

KPTI Street Sentiment is bullish and have positive views on the near-term outlook

KPTI Performance Sentiment

Sentiments overview associated with KPTI events and the stock performance.

62%

38%

Positive

Negative

8 out of 13
events present

5 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$5.59

Resistance
Price

$5.41

Current Price Range

$6.25

Show methods +

KPTI Latest Analysis +

RBC Capital Maintains Karyopharm Therapeutics (KPTI) Outperform Recommendation. Fintel reports that on November 4 2025 RBC Capital maintained coverage of Karyopharm Therapeutics (NasdaqGS:KPTI) with a Outperform recommendation. Analyst Price Forecast Suggests 182.33% Upside

Wed Nov 5, 2025

$5.35 | -5.13%

Potential

Rating

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript November 3 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-3.82132 EPS expectations were $-3.3. Operator: Good morning. My name is Ludy and I will be your conference operator today. At this time I would like to welcome everyone to the Karyopharm Therapeutics [….]

Tue Nov 4, 2025

$5.65 | -6.92%

Earnings

Karyopharm signals $1B annual United States peak revenue opportunity for selinexor in myelofibrosis as SENTRY trial completes enrollment.

Mon Nov 3, 2025

$6.07 | +4.66%

Activity

Potential

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress. – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for – Total Revenue was –– Reaffirms Full-Year 2025 Total Revenue Guidance of – Conference Call Scheduled for Today at ) a commercial-stage pharmaceutical company pioneering novel cancer therapies today reported financial results for the third quarter ended ".This has been a very productive quarter as we have strengthened our

Mon Nov 3, 2025

$6.07 | +4.66%

Activity

Earnings Scheduled For November 3 2025. . CNA Financial (NYSE:CNA) is expected to report quarterly earnings at $1.29 per share on revenue of $3.43 billion. . Ryanair Hldgs (NASDAQ:) is expected to report quarterly earnings at $3.62 per share on revenue of $6.42 billion. . Ares Management (NYSE:ARES) is projected to report quarterly earnings at $1.14 per share on revenue of $1.09 billion. . Loews (NYSE:L) is likely to report earnings for its third quarter. . Pediatrix Medical Group (NYSE:MD) is l

Mon Nov 3, 2025

$6.07 | +4.66%

Earnings

Karyopharm Therapeutics GAAP EPS of -$3.82 misses by $0.30 revenue of $44.04M beats by $1.63M.

Mon Nov 3, 2025

$6.07 | +4.66%

Earnings

FAQ About KPTI Stock Insights

What is KPTI current stock price?

What are KPTI stock strengths?

What risks are associated with KPTI stock?

When is KPTI next earnings report?

What is KPTI market cap and volume?

What is KPTI's current Stock IQ?

Should I buy KPTI stock right now?

Is KPTI a Strong Buy right now?

What does a 'Strong Buy' rating mean for KPTI?

What does a 'Strong Sell' rating mean for KPTI?

What factors influence KPTI's Stock IQ?

Explore our KPTI Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored KPTI Stock Strategies
Effective Risk Management

FIND US ON

Receive our KPTI Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

KPTI

Karyopharm Therapeutics

Current Price

$5.57

+$0.07 | +1.18%

52W High

$ 13.35

MKT CAP

$ 93.78M

52W Low

$ 3.51

VOL

$ 923.00

P/E Ratio

N/A

AVG VOL

$ 245.78K

RSI

44.16

TREND

Downtrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

KPTI Rewards

Earnings are forecast to grow

KPTI Rewards

Outperform the market

KPTI Stock IQ

Login to unlock Karyopharm Therapeutics (KPTI) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$5.99 (-7.01%)

$6.02 (-7.48%)

$4.49 (+24.05%)

$0.85 (+555.29%)

1year

6month

3month

1month

KPTI Analysts Opinion

KPTI Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

KPTI Analysts Opinion

KPTI Analysts opinion is positive and also has improved from the past 3 months

KPTI Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

62%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

100%

KPTI Street Sentiment

KPTI Street Sentiment is bullish and have positive views on the near-term outlook

KPTI Risk Level

KPTI has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Low volume

High volatilty

Moderate

LOW

HIGH

KPTI Performance Sentiment

Sentiments overview associated with KPTI events and the stock performance.

62%

38%

Positive

Negative

8 out of 13
events present

5 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$5.59

Resistance
Price

$5.41

Current Price Range

$6.25

Show methods +

KPTI Latest Analysis

RBC Capital Maintains Karyopharm Therapeutics (KPTI) Outperform Recommendation. Fintel reports that on November 4 2025 RBC Capital maintained coverage of Karyopharm Therapeutics (NasdaqGS:KPTI) with a Outperform recommendation. Analyst Price Forecast Suggests 182.33% Upside

Wed Nov 5, 2025

$5.35 | -5.13%

Potential

Rating

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript November 3 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-3.82132 EPS expectations were $-3.3. Operator: Good morning. My name is Ludy and I will be your conference operator today. At this time I would like to welcome everyone to the Karyopharm Therapeutics [….]

Tue Nov 4, 2025

$5.65 | -6.92%

Earnings

Karyopharm signals $1B annual United States peak revenue opportunity for selinexor in myelofibrosis as SENTRY trial completes enrollment.

Mon Nov 3, 2025

$6.07 | +4.66%

Activity

Potential

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress. – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for – Total Revenue was –– Reaffirms Full-Year 2025 Total Revenue Guidance of – Conference Call Scheduled for Today at ) a commercial-stage pharmaceutical company pioneering novel cancer therapies today reported financial results for the third quarter ended ".This has been a very productive quarter as we have strengthened our

Mon Nov 3, 2025

$6.07 | +4.66%

Activity

Earnings Scheduled For November 3 2025. . CNA Financial (NYSE:CNA) is expected to report quarterly earnings at $1.29 per share on revenue of $3.43 billion. . Ryanair Hldgs (NASDAQ:) is expected to report quarterly earnings at $3.62 per share on revenue of $6.42 billion. . Ares Management (NYSE:ARES) is projected to report quarterly earnings at $1.14 per share on revenue of $1.09 billion. . Loews (NYSE:L) is likely to report earnings for its third quarter. . Pediatrix Medical Group (NYSE:MD) is l

Mon Nov 3, 2025

$6.07 | +4.66%

Earnings

Karyopharm Therapeutics GAAP EPS of -$3.82 misses by $0.30 revenue of $44.04M beats by $1.63M.

Mon Nov 3, 2025

$6.07 | +4.66%

Earnings

Discover KPTI Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of KPTI. We're here to help you make informed investment decisions today.

FIND US ON

Receive our KPTI Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

KPTI Stock trends

KPTI Stock performance

KPTI Stock analysis

KPTI investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing KPTI

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing KPTI

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

KPTI Stock Analysis & IQ Rating | Karyopharm Therapeutics

KPTI Stock IQ

KPTI Target Price

KPTI Risk Level

KPTI Analysts Opinion

KPTI Street Sentiment

KPTI Performance Sentiment

Technical Price Levels

Explore our KPTI Stock insights

Receive our KPTI Daily Alerts

KPTI Stock IQ

KPTI Street Sentiment

KPTI Risk Level

Technical Price Levels

Discover KPTI Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of KPTI. We're here to help you make informed investment decisions today.

Receive our KPTI Daily Alerts

KPTI Runner Alarm